We thank Zeuzem et al. for their response to our recently published findings.
1
,
- Zeuzem S.
- Dvory-Sobol H.
- Brainard D.M.
Reply to: “Response to DAA therapy in the NHS England Early Access Programme for rare
HCV subtypes from low and middle income countries”: No effect of resistance-associated
substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing
regimens.
J Hepatol. 2017; 67: 1350-1352
2
Their data provide a valuable addition to reports describing virological outcomes
for patients infected with “rare” subtypes who have received sofosbuvir (SOF)-based
therapy but have not been well represented in previous large-scale clinical trials.
We agree with the authors that assessing treatment outcome in cohorts infected with
poorly characterized or uncharacterized subtypes would ideally be determined from
patients who have achieved both sustained virological response (SVR) and have had
a treatment relapse. However, well-defined cohorts do not exist in most low- and middle-income
countries (LMICs) where such subtypes are typically found, and consequently the necessary
evidence base has been lacking.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Reply to: “Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries”: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.J Hepatol. 2017; 67: 1350-1352
- Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.J Hepatol. 2017; 67: 1348-1350
- Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?.Lancet Gastroenterol Hepatol. 2017; 2: 700-701
Article info
Publication history
Published online: January 12, 2018
Identification
Copyright
© 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
